JY-039

N/A

Report date: 2024/11/04 17:22:22

Base Information

Drug NameJY-039
Drug Alias NameJY-039
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionNatural killer cells stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsUpdating
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Eastern Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Eastern Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A